Q4 Earnings Estimate for Insulet Issued By Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Analysts at Leerink Partnrs dropped their Q4 2024 EPS estimates for Insulet in a report released on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will post earnings of $0.97 per share for the quarter, down from their previous estimate of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.87 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.20 EPS, FY2025 earnings at $3.89 EPS, FY2026 earnings at $5.21 EPS and FY2027 earnings at $6.49 EPS.

Several other research analysts have also recently weighed in on PODD. Morgan Stanley boosted their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Piper Sandler increased their price target on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. BTIG Research raised their price objective on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Raymond James boosted their target price on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Finally, Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Price Performance

Insulet stock opened at $266.92 on Tuesday. The stock has a market cap of $18.72 billion, a P/E ratio of 45.70, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company’s 50 day moving average price is $242.59 and its two-hundred day moving average price is $212.36. Insulet has a 52 week low of $160.19 and a 52 week high of $279.40.

Institutional Trading of Insulet

A number of institutional investors have recently added to or reduced their stakes in the stock. Synovus Financial Corp boosted its holdings in Insulet by 36.1% in the 3rd quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier’s stock valued at $682,000 after purchasing an additional 777 shares during the period. Tidal Investments LLC raised its position in shares of Insulet by 5.2% in the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier’s stock worth $2,180,000 after buying an additional 466 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Insulet during the third quarter valued at $114,000. Virtu Financial LLC purchased a new position in Insulet during the third quarter worth about $616,000. Finally, TD Private Client Wealth LLC increased its stake in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.